AbbVie, an American pharmaceutical company, completed the acquisition of Landos Biopharma, a clinical stage biopharmaceutical company, for $212m. "Many people living with IBD are not able to achieve or maintain remission and continue to experience debilitating symptoms. The addition of NX-13 complements our portfolio in immunology and strengthens our collective efforts to transform standard of care. I want to commend the Landos team for their efforts in advancing our shared mission of developing medicines for those who need it most," Kori Wallace, AbbVie Vice President, Global Head of Immunology Clinical Development.